Administration of recombinant interleukin-11 improves the hemodynamic functions and decreases third space fluid loss in a porcine model of hemorrhagic shock and resuscitation

Kaneatsu Honma, Nancy L. Koles, Hasan B. Alam, Peter M Rhee, Florence M. Rollwagen, Cara Olsen, James C. Keith, Matthew Pollac

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We have previously demonstrated that the administration of recombinant human interleukin-11 (rhlL-11) during resuscitation improves the blood pressure in a rodent model of hemorrhagic shock. The purpose of this study was to determine whether the effects of rhlL-11 could be reproduced in a large animal model and to elucidate the impact of rhlL-11 administration on the intravascular volume status and the degree of third space fluid loss after resuscitation. A 40% blood volume hemorrhage was induced in swine (n = 45, weight of 25-35 kg) followed by a 1 -h shock period and resuscitation with 0.9% sodium chloride (three times the shed blood volume). The animals were randomized to receive sham hemorrhage (group I, sham); sham hemorrhage and 50 μg/kg rhlL-11 (group II, sham + IL-11); no drug (group III, saline); or 50 μg/kg rhlL-11 (group IV, IL-11). Blood and urine samples were obtained and analyzed at baseline, at the end of hemorrhaging, and thereafter once every hour. The pleural and peritoneal effusions were precisely quantified by using clinically accepted criteria. The mean arterial pressure (MAP) was higher postresuscitation (PR) in groups I, II, and IV (71.4 ± 7.5 mmHg, 71.0 ± 8.9 mmHg, and 72.9 ± 12.3 mmHg, respectively) than in group III (59.9 ± 10.9 mmHg), and the cardiac output of PR was higher in group IV (3.46 ± 0.56 L/min) than in group III (2.99 ± 0.62 L/min; P < 0.01). The difference in MAP between groups I and II became statistically significant at 40 min after rhlL-11 injection and such a difference persisted for 90 min. After resuscitation, the urine output was higher, and the urine specific gravity and third space fluid loss were lower in group IV (1434 ± 325 mL and 1.0035, 82 ± 21 mL) than in group III (958 ± 390 mL and 1.0053, 125 ± 32 mL; P < 0.05). In a porcine model of hemorrhagic shock, the administration of rhlL-11 at the start of resuscitation significantly improved the cardiac output and blood pressure. This strategy also significantly reduced the extent of third space fluid losses while also having a favorable impact on the intravascular volume status as evidenced by the improved urine output.

Original languageEnglish (US)
Pages (from-to)539-542
Number of pages4
JournalShock (Augusta, Ga.)
Volume23
Issue number6
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Interleukin-11
Hemorrhagic Shock
Resuscitation
Swine
Hemodynamics
Urine
Hemorrhage
Blood Volume
Cardiac Output
Arterial Pressure
Blood Pressure
Specific Gravity
Ascitic Fluid
Pleural Effusion
Sodium Chloride
Rodentia
Shock
Animal Models
Weights and Measures
Injections

Keywords

  • Effusion
  • Hemorrhagic shock
  • Homodynamic
  • Recombinant human interleukin-11
  • Urine output

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Physiology

Cite this

Administration of recombinant interleukin-11 improves the hemodynamic functions and decreases third space fluid loss in a porcine model of hemorrhagic shock and resuscitation. / Honma, Kaneatsu; Koles, Nancy L.; Alam, Hasan B.; Rhee, Peter M; Rollwagen, Florence M.; Olsen, Cara; Keith, James C.; Pollac, Matthew.

In: Shock (Augusta, Ga.), Vol. 23, No. 6, 06.2005, p. 539-542.

Research output: Contribution to journalArticle

Honma, Kaneatsu ; Koles, Nancy L. ; Alam, Hasan B. ; Rhee, Peter M ; Rollwagen, Florence M. ; Olsen, Cara ; Keith, James C. ; Pollac, Matthew. / Administration of recombinant interleukin-11 improves the hemodynamic functions and decreases third space fluid loss in a porcine model of hemorrhagic shock and resuscitation. In: Shock (Augusta, Ga.). 2005 ; Vol. 23, No. 6. pp. 539-542.
@article{f7a59495cdfe4a5abc2db677f10128bc,
title = "Administration of recombinant interleukin-11 improves the hemodynamic functions and decreases third space fluid loss in a porcine model of hemorrhagic shock and resuscitation",
abstract = "We have previously demonstrated that the administration of recombinant human interleukin-11 (rhlL-11) during resuscitation improves the blood pressure in a rodent model of hemorrhagic shock. The purpose of this study was to determine whether the effects of rhlL-11 could be reproduced in a large animal model and to elucidate the impact of rhlL-11 administration on the intravascular volume status and the degree of third space fluid loss after resuscitation. A 40{\%} blood volume hemorrhage was induced in swine (n = 45, weight of 25-35 kg) followed by a 1 -h shock period and resuscitation with 0.9{\%} sodium chloride (three times the shed blood volume). The animals were randomized to receive sham hemorrhage (group I, sham); sham hemorrhage and 50 μg/kg rhlL-11 (group II, sham + IL-11); no drug (group III, saline); or 50 μg/kg rhlL-11 (group IV, IL-11). Blood and urine samples were obtained and analyzed at baseline, at the end of hemorrhaging, and thereafter once every hour. The pleural and peritoneal effusions were precisely quantified by using clinically accepted criteria. The mean arterial pressure (MAP) was higher postresuscitation (PR) in groups I, II, and IV (71.4 ± 7.5 mmHg, 71.0 ± 8.9 mmHg, and 72.9 ± 12.3 mmHg, respectively) than in group III (59.9 ± 10.9 mmHg), and the cardiac output of PR was higher in group IV (3.46 ± 0.56 L/min) than in group III (2.99 ± 0.62 L/min; P < 0.01). The difference in MAP between groups I and II became statistically significant at 40 min after rhlL-11 injection and such a difference persisted for 90 min. After resuscitation, the urine output was higher, and the urine specific gravity and third space fluid loss were lower in group IV (1434 ± 325 mL and 1.0035, 82 ± 21 mL) than in group III (958 ± 390 mL and 1.0053, 125 ± 32 mL; P < 0.05). In a porcine model of hemorrhagic shock, the administration of rhlL-11 at the start of resuscitation significantly improved the cardiac output and blood pressure. This strategy also significantly reduced the extent of third space fluid losses while also having a favorable impact on the intravascular volume status as evidenced by the improved urine output.",
keywords = "Effusion, Hemorrhagic shock, Homodynamic, Recombinant human interleukin-11, Urine output",
author = "Kaneatsu Honma and Koles, {Nancy L.} and Alam, {Hasan B.} and Rhee, {Peter M} and Rollwagen, {Florence M.} and Cara Olsen and Keith, {James C.} and Matthew Pollac",
year = "2005",
month = "6",
doi = "10.1097/01.shk.0000162235.37135.dc",
language = "English (US)",
volume = "23",
pages = "539--542",
journal = "Shock",
issn = "1073-2322",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Administration of recombinant interleukin-11 improves the hemodynamic functions and decreases third space fluid loss in a porcine model of hemorrhagic shock and resuscitation

AU - Honma, Kaneatsu

AU - Koles, Nancy L.

AU - Alam, Hasan B.

AU - Rhee, Peter M

AU - Rollwagen, Florence M.

AU - Olsen, Cara

AU - Keith, James C.

AU - Pollac, Matthew

PY - 2005/6

Y1 - 2005/6

N2 - We have previously demonstrated that the administration of recombinant human interleukin-11 (rhlL-11) during resuscitation improves the blood pressure in a rodent model of hemorrhagic shock. The purpose of this study was to determine whether the effects of rhlL-11 could be reproduced in a large animal model and to elucidate the impact of rhlL-11 administration on the intravascular volume status and the degree of third space fluid loss after resuscitation. A 40% blood volume hemorrhage was induced in swine (n = 45, weight of 25-35 kg) followed by a 1 -h shock period and resuscitation with 0.9% sodium chloride (three times the shed blood volume). The animals were randomized to receive sham hemorrhage (group I, sham); sham hemorrhage and 50 μg/kg rhlL-11 (group II, sham + IL-11); no drug (group III, saline); or 50 μg/kg rhlL-11 (group IV, IL-11). Blood and urine samples were obtained and analyzed at baseline, at the end of hemorrhaging, and thereafter once every hour. The pleural and peritoneal effusions were precisely quantified by using clinically accepted criteria. The mean arterial pressure (MAP) was higher postresuscitation (PR) in groups I, II, and IV (71.4 ± 7.5 mmHg, 71.0 ± 8.9 mmHg, and 72.9 ± 12.3 mmHg, respectively) than in group III (59.9 ± 10.9 mmHg), and the cardiac output of PR was higher in group IV (3.46 ± 0.56 L/min) than in group III (2.99 ± 0.62 L/min; P < 0.01). The difference in MAP between groups I and II became statistically significant at 40 min after rhlL-11 injection and such a difference persisted for 90 min. After resuscitation, the urine output was higher, and the urine specific gravity and third space fluid loss were lower in group IV (1434 ± 325 mL and 1.0035, 82 ± 21 mL) than in group III (958 ± 390 mL and 1.0053, 125 ± 32 mL; P < 0.05). In a porcine model of hemorrhagic shock, the administration of rhlL-11 at the start of resuscitation significantly improved the cardiac output and blood pressure. This strategy also significantly reduced the extent of third space fluid losses while also having a favorable impact on the intravascular volume status as evidenced by the improved urine output.

AB - We have previously demonstrated that the administration of recombinant human interleukin-11 (rhlL-11) during resuscitation improves the blood pressure in a rodent model of hemorrhagic shock. The purpose of this study was to determine whether the effects of rhlL-11 could be reproduced in a large animal model and to elucidate the impact of rhlL-11 administration on the intravascular volume status and the degree of third space fluid loss after resuscitation. A 40% blood volume hemorrhage was induced in swine (n = 45, weight of 25-35 kg) followed by a 1 -h shock period and resuscitation with 0.9% sodium chloride (three times the shed blood volume). The animals were randomized to receive sham hemorrhage (group I, sham); sham hemorrhage and 50 μg/kg rhlL-11 (group II, sham + IL-11); no drug (group III, saline); or 50 μg/kg rhlL-11 (group IV, IL-11). Blood and urine samples were obtained and analyzed at baseline, at the end of hemorrhaging, and thereafter once every hour. The pleural and peritoneal effusions were precisely quantified by using clinically accepted criteria. The mean arterial pressure (MAP) was higher postresuscitation (PR) in groups I, II, and IV (71.4 ± 7.5 mmHg, 71.0 ± 8.9 mmHg, and 72.9 ± 12.3 mmHg, respectively) than in group III (59.9 ± 10.9 mmHg), and the cardiac output of PR was higher in group IV (3.46 ± 0.56 L/min) than in group III (2.99 ± 0.62 L/min; P < 0.01). The difference in MAP between groups I and II became statistically significant at 40 min after rhlL-11 injection and such a difference persisted for 90 min. After resuscitation, the urine output was higher, and the urine specific gravity and third space fluid loss were lower in group IV (1434 ± 325 mL and 1.0035, 82 ± 21 mL) than in group III (958 ± 390 mL and 1.0053, 125 ± 32 mL; P < 0.05). In a porcine model of hemorrhagic shock, the administration of rhlL-11 at the start of resuscitation significantly improved the cardiac output and blood pressure. This strategy also significantly reduced the extent of third space fluid losses while also having a favorable impact on the intravascular volume status as evidenced by the improved urine output.

KW - Effusion

KW - Hemorrhagic shock

KW - Homodynamic

KW - Recombinant human interleukin-11

KW - Urine output

UR - http://www.scopus.com/inward/record.url?scp=18744403687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744403687&partnerID=8YFLogxK

U2 - 10.1097/01.shk.0000162235.37135.dc

DO - 10.1097/01.shk.0000162235.37135.dc

M3 - Article

VL - 23

SP - 539

EP - 542

JO - Shock

JF - Shock

SN - 1073-2322

IS - 6

ER -